Gnathostomiasis is a foodborne zoonotic helminthic infection caused by the third-stage larvae of *Gnathostoma* spp. nematodes. The most severe manifestation involves infection of the central nervous system, neurognathostomiasis. Although gnathostomiasis is endemic to Asia and Latin America, almost all neurognathostomiasis cases are reported from Thailand. Despite high rates of illness and death, neurognathostomiasis has received less attention than the more common cutaneous form of gnathostomiasis, possibly because of the apparent geographic confinement of the neurologic infection to 1 country. Recently, however, the disease has been reported in returned travelers in Europe. We reviewed the English-language literature on neurognathostomiasis and analyzed epidemiology and geographic distribution, mode of central nervous system invasion, pathophysiology, clinical features, neuroimaging data, and treatment options. On the basis of epidemiologic data, clinical signs, neuroimaging, and laboratory findings, we propose diagnostic criteria for neurognathostomiasis.
Foodborne parasitic infections are common in the tropics, where many foodborne parasites are endemic and ingestion of raw shellfish and freshwater fish, as well as undercooked meat, is frequent among local populations (1). Increased international travel to areas endemic for these foodborne parasites and migration from tropical areas have led to the emergence of these diseases in temperate climates (2), where such infections are rarely seen by physicians and thus may not be considered in differential diagnoses. Gnathostomiasis is a foodborne zoonotic helminthic infection caused by the third-stage larva of *Gnathostoma* spp. nematodes (Figure 1, panels A, B). At least 13 species have been identified (3), with 5 recorded in humans. *G. spinigerum* is the most common of these nematodes in Asia. Human infection with *G. hispidum*, *G. doloresi*, and *G. nipponicum* were found only in Japan (4). In the Americas, *G. binucleatum* is the only proven pathogenic *Gnathostoma* nematode in humans. Humans are infected primarily by eating raw or undercooked freshwater fish (Figure 1, panel C), frogs, and chicken. Humans are accidental unsuitable hosts; the parasite rarely develops to an adult worm, and the disease in humans is caused by the migrating larva.

Gnathostomiasis can be divided into cutaneous, visceral, and ocular forms, depending on the site of larval migration and subsequent signs and symptoms (2). The most common clinical presentation is the cutaneous one (Figure 1, panel D), which is characterized by localized, intermittent, migratory swellings of the skin and is often associated with localized pain, pruritus, and erythema (5,6). Visceral involvement can manifest in virtually any organ and any part of the body (3). The most severe manifestation of the visceral disease is involvement of the central nervous system (CNS), i.e., neurognathostomiasis. Neurognathostomiasis has been reported only in *G. spinigerum* infections (3).

We found 24 reports describing a total of 248 patients with neurognathostomiasis published in English-language literature. In this article, we review epidemiology, mode of CNS invasion, pathophysiology, clinical features, neuroimaging data, and treatment options, and we propose diagnostic criteria for this emerging disease.

History of Neurognathostomiasis

The first clinical case of *G. spinigerum* meningoencephalitis was reported by Daensvang in 1949 (7). Eighteen years later, Chitanondh and Rosen (8) documented the first pathologic evidence of *G. spinigerum* invasion of the CNS from the autopsy of a 34-year-old Thai woman. In their seminal study, Boongird et al. (9)
delineated the clinical syndromes of neurognathostomiasis, which facilitated further prospective and retrospective case identification (10). With the advance of high-resolution neuroimaging, the parasitic tracks of *Gnathostoma* could be demonstrated on magnetic resonance imaging (MRI), aiding the diagnosis of neurognathostomiasis in the absence of worm recovery (11).

**Epidemiology of Neurognathostomiasis**

Most (241/248) identified cases of neurognathostomiasis reported in the English-language literature were from Thailand. Two patients were infected in Laos (12,13), 1 in Japan (14), 1 in Myanmar (13), and 2 in South Korea (15,16). One patient had traveled to Southeast Asia and Japan (17), so the geographic origin of his infection could not be determined. The incubation period of neurognathostomiasis can be as long as 10 years because of the long persistence of the nematode larvae in the soft tissues before CNS invasion (2,15), which means it can occur in immigrants in a country in which the parasite is not endemic (16,18). All case-patients were reported to have been infected with *G. spinigerum*. Although gnathostomiasis has been increasingly detected outside of Asia, particularly in Mexico, no cases of neurognathostomiasis have been reported in other regions. The occurrence of another *Gnathostoma* species in Latin America, namely *G. binucleatum*, is a possible explanation for this phenomenon.

**Neurognathostomiasis in Travelers**

The first case of neurognathostomiasis in a traveler was reported in 2003 (19). Since then, 4 patients in Europe returning from gnathostomiasis-endemic countries have been published (13,20,21). Two patients traveled to Thailand (19,20), 1 patient to Lao People’s Democratic Republic (13) and 1 patient to Myanmar (13). The patients were reported to have indulged in local customs of eating raw fish (19) and shrimp (20). Gnathostomiasis has been recently reported in travelers returning from southern Africa (22,23). However, the patients had cutaneous manifestation of *Gnathostoma* spp. infection without neurologic involvement.

**Pathophysiology of Neurognathostomiasis**

*Gnathostoma* spp. nematodes are highly invasive parasites. After being ingested, the third-stage larvae penetrate the mucosal wall of the gastrointestinal tract. Larvae can enter the CNS by invading directly through the loose connective tissues of the neural foramina of the skull base along the cranial nerves and vessels or through intervertebral foramina along the spinal nerves and vessels (24). The larvae release a variety of molecules into their surrounding environment that facilitate tissue penetration and invasion (25). Proteases are the major molecular types among various components of these so-called excretor–secretory products, both quantitatively and qualitatively (26). In *Gnathostoma* spp., matrix metalloproteinases might play a key role in invasion of host tissues (27).

*Gnathostoma* spp. nematodes typically enter the spinal cord along the nerve roots, causing radiculomyelitis (9,28). The parasite is then able to ascend the spinal cord and reach the brain (3,29). This journey may take as long as several years and has been documented in a Thai patient through sequential imaging (29).

Given the length of the migrating larva, which averages 3.0 mm (30), the migration of the worm in the CNS causes direct mechanical injury because of tearing of nerve tissue. The hallmark sign of neurognathostomiasis is the evidence of multiple hemorrhagic tracks; these tracks have been documented throughout the spinal cord and brain tissue by postmortem examination (9), as well as through neuroimaging (31). Subarachnoid hemorrhage can result from larvae burrowing through a cerebral arteriole (32,33). Eosinophilic meningitis caused by *Gnathostoma* spp. is characterized by erythrocytes in cerebrospinal fluid (CSF) (33), which suggests mechanical damage by the worm. Apart from the structural damage, the inflammatory response to the migrating larvae might further contribute to tissue destruction (34).

**Clinical Signs of Neurologic Involvement**

The main clinical syndromes of neurognathostomiasis are radiculomyelitis/radiculomyeloencephalitis, meningitis/meningoencephalitis, and subarachnoid and intracerebral hemorrhage (Table 1). Each syndrome reflects the tissue injury by the migrating parasite. Because the larvae migrate, the same patient can show sequentially different neurologic syndromes. For example, in 1 Laotian patient, meningomyelitis developed, followed by subarachnoid hemorrhage (12). Meningitis, subdural hemorrhage, and then intraparenchymal lesions developed sequentially in 1 patient from northeastern Thailand (29). The most common symptom reported virtually by every patient was pain: radicular pain in cases of spinal involvement (often lasting 1–5 days) or headache in cases of meningonecephalitis. The most common manifestation, spinal cord disease, accounted for 55% of all clinical syndromes (Table 1).

Myelopathy in gnathostomiasis is characterized by radicular pain followed by an ascending paresis of lower extremities or quadripleasis with bladder dysfunction (9,10,33,35–38). A sensory level for all modalities including vibration and proprioception was a frequent finding, commonly localized in the thoracic region (9). Cerebral and meningeal involvement is characterized by meningeal signs and decreased consciousness. Abducent nerve palsy was the most common cranial nerve impairment.
Neurognathostomiasis

Intracranial hemorrhages were seen with sudden-onset focal neurologic deficits such as hemiparesis and hemihypaesthesia (9,10,18,33).

Isolated Neurologic Disease

The most common clinical feature of gnathostomiasis is intermittent migratory cutaneous swelling (5). However, in the largest published series of neurognathostomiasis in 162 patients, only 11 (7%) had a history of cutaneous lesions (10). Unilateral eyelid swelling, another typical sign of gnathostomiasis, occurred in only 6 patients (4%) (10). Boongird et al. reported only 3 patients with subcutaneous swelling out of 24 patients with neurognathostomiasis; cutaneous gnathostomiasis developed in all of these patients after the onset of neurologic symptoms (9).

CSF Studies

Eosinophilic pleocytosis is a hallmark laboratory finding. CSF eosinophilia in patients is usually prominent; median values were 40% (n = 24) and 54% (n = 39) in the studies by Boongird et al (9) and Schmutzhard et al (33), respectively. In 109 (67%) of patients reported by Punyagupta et al. (10), the eosinophil count in CSF was >30%. CSF has been reported as xanthochromic or bloody in 134 patients (64% of all published cases). CSF glucose is usually only mildly reduced but was reported as low as 11 mg/dL (9% of the plasma value) in 1 patient (37).

Neuroradiologic Features

Neuroimaging of 11 patients with neurognathostomiasis was reported in English-language literature. On cranial computed tomography, subarachnoid hemorrhage and intracerebral hemorrhage were the most common findings (12,18,33). In 1 patient a subdural hemorrhage was detected (29). The hallmark of cerebral gnathostomiasis on MRI was the detection of hemorrhagic tracks (Figure 2, panels A, C, D). The magnetic resonance signal of a hemorrhagic lesion varies in acute, subacute, and chronic lesions. Hence, on T1 and T2 weighted imaging both hypointensities and hyperintensities have been documented. No gradient-echo T2-weighted sequences have been reported in neurognathostomiasis. However, gradient-echo T2-weighted sequences are exquisitely sensitive to local field inhomogeneities of hematoma and could become a useful sequence in radiologic assessment of cerebral gnathostomiasis.

Table 1. Clinical presentation of 248 patients with neurognathostomiasis*

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Probable entry portal entry</th>
<th>Clinical signs and symptoms</th>
<th>No. (%) cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiculomyelitis/myelitis/myeloencephalitis</td>
<td>Intervertebral foramina along the spinal nerves and vessels</td>
<td>Sharp radicular pain and a spinal syndrome (paraplegia, monoplegia, quadriplegia, bladder dysfunction, sensory disturbances), can progress to cerebral involvement (myeloencephalitis)</td>
<td>140 (55)</td>
</tr>
<tr>
<td>Meningitis/meningoencephalitis</td>
<td>Neural foramina of the skull base along the cranial nerves and vessels</td>
<td>Severe headache, stiffness of the neck, cranial nerve palsies, disturbance of consciousness, focal neurologic signs</td>
<td>77 (30)</td>
</tr>
<tr>
<td>Intracerebral hemorrhage</td>
<td>Intervertebral or neural foramina</td>
<td>Headache, sudden-onset focal neurologic signs</td>
<td>21 (8)</td>
</tr>
<tr>
<td>Subarachnoid hemorrhage</td>
<td>Intervertebral or neural foramina</td>
<td>Thunderclap headache, meningeal signs</td>
<td>16 (7)</td>
</tr>
</tbody>
</table>

*Because the larvae migrate, patients can have sequential signs and symptoms; thus, the total number of clinical syndromes shown exceeds the number of reported patients.

(9,33). Intracranial hemorrhages were seen with sudden-onset focal neurologic deficits such as hemiparesis and hemihypaesthesia (9,10,18,33).

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 7, July 2011

Figure 2. Images of the brains of patients with cerebral gnathostomiasis. A) Axial T1-weighted image showing small hemorrhage in the right basal ganglia (arrow). B) Sagittal T2-weighted images showing diffuse cord enlargement with longitudinal T2 hyperintensity (arrows). C) Axial T1-weighted image showing a hemorrhagic track in the tegmentum of the pons (arrow). D) Coronal T1-weighted postgadolinium image, showing the longitudinal extension of the same hemorrhagic track as in panel C (arrows). Images from K. Sawanyawisuth et al. (11), used with permission.
Diffuse multisegmental spinal cord swelling with corresponding T2 hyperintensities was the most common finding on spinal imaging (11,17) (Figure 2, panel B). Gadolinium enhancement of the lesions was reported in cranial and spinal MRI of 4 patients as slight, nodular, and ill-defined (11,17,35). Table 2 summarizes typical findings on neuroimaging in neurognathostomiasis.

Immunodiagnosis

The detection of antibodies in serum is the main pillar of immunodiagnosis of gnathostomiasis. Two methods have been established for clinical routine: ELISA and Western blot by using crude Gnathostoma spp. antigens from the larval extract. The 24-kD band on Western blot was shown to have nearly 100% specificity for gnathostomiasis (39). The current practice for serologic diagnosis is to use the ELISA (e.g., multiple-dot ELISA) as the first step (40) and to confirm the results by Western blot. At least 2 patients seroconverted during their neurologic illness (19,20), which emphasizes the need for repeated serologic examination in cases with strong clinical suspicion. The serologic testing can be done in several laboratories, including those in Thailand (Bangkok, Khon Kaen), Japan (Miayzaki), and Europe (Basel, Switzerland). Additional information about laboratories providing this service is available from the corresponding author.

Differential Diagnosis

The main differential diagnosis of neurognathostomiasis is an infection with Angiostrongylus cantonensis. However, Angiostrongylus spp. infection is usually seen as self-limited eosinophilic meningitis and only rarely causes severe disease with prominent spinal or cerebral involvement (1). Immunodiagnostically, positive 24-kD band against G. spinigerum antigen and negative 29-kD and 31-kD bands on immunoblot against A. cantonensis antigen make a diagnosis of an Angiostrongylus spp. infection highly unlikely (40). Other causes of a parasitic CNS disease, such as cysticercosis, toxocariasis, schistosomiasis, baylisascariasis, or paragonimiasis, can be distinguished by epidemiologic distribution, clinical signs and symptoms, radiologic appearance, and serologic testing.

Treatment

No randomized trials of antihelminthic therapy have been conducted for neurognathostomiasis. We have identified 9 reports of treatment of neurognathostomiasis with albendazole (11,13,17–21,29); 5 patients fully recovered, 2 partially recovered, and 2 patients did not recover. Outcomes might reflect the natural course of the disease rather than the effect of treatment. In several reports, antihelminthic treatment was considered as potentially detrimental and was withheld on the basis of its possible induction of brain edema due to sudden hemilinmic death (31,38). Three returned travelers from Thailand were treated with albendazole (800 mg/d for 1 month [19], 800 mg/d for 3 weeks [20], and 400 mg 2×/d for 4 weeks [21]) and fully recovered (19–21). In all these patients, dexamethasone (oral or intravenous) or prednisolone was added to the treatment regimen. A recent retrospective evaluation of long-term treatment efficacy in 13 patients from France with imported gnathostomiasis reported 2 patients with neurologic involvement (13), 1 with myelitis, and 1 with encephalitis (C. Strady, pers. comm.). The patient with myelitis fully recovered after albendazole therapy, and the patient with encephalitis was reported to have had 4 relapses despite therapy with ivermectin and albendazole (13; C. Strady, pers. comm.).

Corticosteroids have been used in neurognathostomiasis to treat cerebral and spinal edema (19–21). They also might prevent or alleviate paradoxical worsening after initiation of antihelminthic treatment. However, no conclusion about their efficacy can be drawn from the current data because no randomized control trials have been conducted and the retrospective data are too limited to allow any comparison between the groups. At the moment, no evidence-based recommendations can be issued.

Outcome

The case-fatality rate in the first series of 24 patients was 25% (9). Later studies reported mortality rates of 7%–12% (10,33). However, as the authors remark, these case-fatality rates are almost certainly an underestimate because many patients in critical condition were discharged home to die (10). In total, the outcome of 247 patients has been reported in the literature. An unfavorable outcome, e.g., death or severe persistent disability, was reported in 78 patients (32%). However, the recent case reports indicate that the current prognosis might be better. Of 15 patients in whom neurognathostomiasis was diagnosed after 2001, poor outcomes were reported in 3 (20%) patients. In all 4

<table>
<thead>
<tr>
<th>Site</th>
<th>Procedure</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>CT</td>
<td>Parenchymal (single or multiple), subdural or subarachnoid hyperintensities corresponding to intracranial hemorrhage</td>
</tr>
<tr>
<td>MRI</td>
<td>Multiple (worm-like) T2-weighted hyperintensities or hypointensities in both hemispheres and the cerebellum of ≥3 mm diameter (hemorrhagic tracks) with or without gadolinium enhancement</td>
<td></td>
</tr>
<tr>
<td>Spinal cord</td>
<td>MRI</td>
<td>Dilatation/swelling of the spinal cord with multisegmental T2-weighted hyperintensities, frequent gadolinium enhancement (slight to moderate) on T1 postcontrast images</td>
</tr>
</tbody>
</table>

*CT, computed tomography; MRI, magnetic resonance imaging.

Table 2. Neuroradiologic features of neurognathostomiasis

SYNOPSIS

No randomized trials of antihelminthic therapy have been conducted for neurognathostomiasis. We have identified 9 reports of treatment of neurognathostomiasis with albendazole (11,13,17–21,29); 5 patients fully recovered, 2 partially recovered, and 2 patients did not recover. Outcomes might reflect the natural course of the disease rather than the effect of treatment. In several reports, antihelminthic treatment was considered as potentially detrimental and was withheld on the basis of its possible induction of brain edema due to sudden hemilinmic death (31,38). Three returned travelers from Thailand were treated with albendazole (800 mg/d for 1 month [19], 800 mg/d for 3 weeks [20], and 400 mg 2×/d for 4 weeks [21]) and fully recovered (19–21). In all these patients, dexamethasone (oral or intravenous) or prednisolone was added to the treatment regimen. A recent retrospective evaluation of long-term treatment efficacy in 13 patients from France with imported gnathostomiasis reported 2 patients with neurologic involvement (13), 1 with myelitis, and 1 with encephalitis (C. Strady, pers. comm.). The patient with myelitis fully recovered after albendazole therapy, and the patient with encephalitis was reported to have had 4 relapses despite therapy with ivermectin and albendazole (13; C. Strady, pers. comm.).

Corticosteroids have been used in neurognathostomiasis to treat cerebral and spinal edema (19–21). They also might prevent or alleviate paradoxical worsening after initiation of antihelminthic treatment. However, no conclusion about their efficacy can be drawn from the current data because no randomized control trials have been conducted and the retrospective data are too limited to allow any comparison between the groups. At the moment, no evidence-based recommendations can be issued.

Outcome

The case-fatality rate in the first series of 24 patients was 25% (9). Later studies reported mortality rates of 7%–12% (10,33). However, as the authors remark, these case-fatality rates are almost certainly an underestimate because many patients in critical condition were discharged home to die (10). In total, the outcome of 247 patients has been reported in the literature. An unfavorable outcome, e.g., death or severe persistent disability, was reported in 78 patients (32%). However, the recent case reports indicate that the current prognosis might be better. Of 15 patients in whom neurognathostomiasis was diagnosed after 2001, poor outcomes were reported in 3 (20%) patients. In all 4

<table>
<thead>
<tr>
<th>Site</th>
<th>Procedure</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>CT</td>
<td>Parenchymal (single or multiple), subdural or subarachnoid hyperintensities corresponding to intracranial hemorrhage</td>
</tr>
<tr>
<td>MRI</td>
<td>Multiple (worm-like) T2-weighted hyperintensities or hypointensities in both hemispheres and the cerebellum of ≥3 mm diameter (hemorrhagic tracks) with or without gadolinium enhancement</td>
<td></td>
</tr>
<tr>
<td>Spinal cord</td>
<td>MRI</td>
<td>Dilatation/swelling of the spinal cord with multisegmental T2-weighted hyperintensities, frequent gadolinium enhancement (slight to moderate) on T1 postcontrast images</td>
</tr>
</tbody>
</table>

*CT, computed tomography; MRI, magnetic resonance imaging.

Table 2. Neuroradiologic features of neurognathostomiasis
clinical cases of returned travelers with myelitis, recovery was good after antihelminthic therapy (13,19–21).

Conclusions

Definitive diagnosis of helminthic CNS infections is notoriously difficult. The recovery rate of worms from the CSF is low, and the invasive procedures for diagnosis are seldom justified (33,35). Neurognathostomiasis is no exception; of 248 published cases, only 27 (11%) were confirmed by recovery of larvae. Moreover, an intermittent subcutaneous swelling, the hallmark of gnathostomiasis, is found only in the minority of neurognathostomiasis cases. Given these difficulties, clinical criteria are useful for practice and research. On the basis of the analysis of published cases, we propose diagnostic criteria that should guide a clinician if a pathologic diagnosis is not possible (Table 3).

Neurognathostomiasis is a parasitic CNS disease endemic to Southeast Asia, particularly Thailand. Because of growing international travel to disease-endemic areas, as well as migration from the tropics, an increasing number of patients will seek medical attention in Europe and North America. Neurognathostomiasis should be suspected in patients who have eosinophilic radiculomyelitis, myeloencephalitis or meningoencephalitis, and a history of travel to gnathostomiasis-endemic areas. Ingestion of raw or inadequately cooked shellfish, freshwater fish, or poultry is a prerequisite for infection; however, because such information might not be volunteered by the patient, clinicians should ask directly about foods eaten during travel. Serologic testing, including Western blot, shows high specificity and can contribute to the diagnosis in an appropriate clinical and epidemiologic setting. No evidence-based protocol is available for treatment of neurognathostomiasis; however, a 3- to 4-week course of albendazole with prednisolone or dexamethasone is 1 of the most frequently used regimens. Clinicians should advise patients traveling to or living in disease-endemic areas to avoid eating undercooked freshwater fish, frogs, poultry, and shellfish.

Dr Katchanov is a neurologist and a member of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. He has a special interest in neuroinfectious disorders, particularly bacterial meningitis, and neurohelminthiasis.

Table 3. Proposed diagnostic criteria for neurognathostomiasis

<table>
<thead>
<tr>
<th><strong>Epidemiologic criteria</strong></th>
<th><strong>Clinical syndrome</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Travel or residence in the disease-endemic area</td>
<td>Painful radiculomyelitis/radiculomyeloencephalitis</td>
</tr>
<tr>
<td>AND exposure to undercooked freshwater fish, frogs, poultry, and shellfish</td>
<td>OR meningitis/meningoencephalitis</td>
</tr>
<tr>
<td></td>
<td>OR intracerebral hemorrhage</td>
</tr>
<tr>
<td></td>
<td>OR subarachnoid hemorrhage</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Indirect evidence of CNS invasion</strong></th>
<th><strong>Immunodiagnosis</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF studies: eosinophilic pleocytosis</td>
<td>Positive detection of reactivity against the 24-kDa component of <em>Gnathostoma spinigerum</em> in immunoblot test</td>
</tr>
<tr>
<td>OR neuroimaging: parenchymal hemorrhagic tracks (&gt;3 mm)</td>
<td>Activity of reactivity against the 29–31-kDa components of <em>Angiostrongylus cantonensis</em> in immunoblot test</td>
</tr>
</tbody>
</table>

*All criteria should be fulfilled for clinical diagnosis of neurognathostomiasis. CNS, central nervous system; CSF, cerebrospinal fluid.†If negative, a follow-up examination 4 weeks later is recommended.

References

20. Elzi L, Decker M, Battegay M, Rutishauser C, Godfrey-Faussett P, Bai-
22. Herman JS, Wall EC, van-Tulleken C, Godfrey-Faussett P, Bailey RL, Chi-
38. Sawanyawisuth K, Tiamkao S, Nitinavakarn B, Dekumyoy P, Jitimo-

Address for correspondence: Yukifumi Nawa, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Rd, Bangkok 10400, Thailand; email: yukifuminawa@fc.miyazaki-u.ac.jp